Begin main content

CADTH pan-Canadian Oncology Drug Review

The pan-Canadian Oncology Drug Review (pCODR) is an evidence-based, cancer drug review process.

The pCODR process is designed to bring consistency and clarity to the assessment of cancer drugs by reviewing clinical evidence, cost-effectiveness, and patient perspectives, and using this information to make recommendations to Canada's provinces and territories (except Quebec) in guiding their drug funding decisions.

Drug Review Updates

Alectinib (Alecensaro) for Non-Small Cell Lung Cancer (first line)
(Open for Feedback on Recommendation until July 20, 2018)

Inotuzumab Ozogamicin (Besponsa) for Acute Lymphoblastic Leukemia
(Final Recommendation Issued as of July 6, 2018)

Trifluridine and Tipiracil (Lonsurf) for Metastatic Colorectal Cancer
(Final Recommendation Issued as of July 6, 2018)

Atezolizumab (Tecentriq) for Non-Small Cell Lung Cancer 
(Notification to Implement Issued as of July 6, 2018)

Lutetium Lu 177 dotatate (Lutathera) for Gastroenteropancreatic Neuroendocrine Tumors
(Pending Submission as of May 9, 2018)

 

 

Find a Drug Review